Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial NeoplasiaAndrea DeCensi, Bernardo Bonanni, Matteo Puntoni et al.|Journal of Clinical Oncology|2019Cited by 218
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 studyMarina Elena Cazzaniga, Massimiliano Mazza, G. Pinotti et al.|The Breast|2019Cited by 58
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.PierFranco Conte, Valentina Guarneri, Elisa Picardo et al.|Journal of Clinical Oncology|2017Cited by 36
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 studyMarina Elena Cazzaniga, I. Vallini, Emilia Montagna et al.|Breast Cancer Research and Treatment|2021Cited by 17
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratioPierFranco Conte, Roberto D’Amico, Valentina Guarneri et al.|Annals of Oncology|2018Cited by 6